Evercore ISI Reiterates Bullish View on Adamas Pharmaceuticals (ADMS)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. BROS
3. ARM
4. FIS
5. QCOM
6. EXPE
7. CPAY
8. PAYC
9. SNAP
10. FSLY

Go back to Evercore ISI Reiterates Bullish View on Adamas Pharmaceuticals (ADMS)

Adamas Pharmaceuticals (ADMS) PT Lowered to $7 at Piper Jaffray

December 17, 2019 1:57 PM EST

Piper Jaffray analyst David Amsellem lowered the price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $7.00 (from $11.00) while maintaining a Overweight rating.

MS gait not dead, but certainly not alive and well... More

Adamas Pharma (ADMS) Resumes After Halt for News, Now Halted on LUDP

December 17, 2019 9:51 AM EST

Adamas Pharma (NASDAQ: ADMS) Resumes After Halt for News, Now Halted on LUDP

... More

Adamas Pharma (ADMS) to Resume Trading at 9:50 am ET

December 17, 2019 9:04 AM EST

Adamas Pharma (NASDAQ: ADMS) to Resume Trading at 9:50 am ET

... More

Adamas (ADMS) phase 3 trial of ADS-5102 for MS patients with walking impairment met its primary endpoint, did not demonstrate significant effect on secondary walking measures

December 17, 2019 9:03 AM EST

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that INROADS, a 3-arm, randomized, double-blind, placebo-controlled study in 594 multiple sclerosis (MS) patients with walking impairment met its primary endpoint.

Results from the study showed that patients taking 274 mg ADS-5102 had a statistically significant improvement in response rate of 21.1% compared to 11.3% taking placebo (p=0.01). Response was defined as at least a 20% improvement in walking speed from baseline to 12 weeks post-treatment, as measured... More